drug

pralsetinib

1 story · latest Oct 20, 2026

Follow pralsetinib. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: FDA approved Sep 2020 · NDA213721, NDA214701
Brand: Gavreto
Trials: 1 registered trial in coverage

Relationships

Developed by Roche

Timeline

FDA approves pralsetinib for RET fusion-positive non-small cell lung cancer

Oct 20Regulatory decisionpralsetinib

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.